Eltrombopag Polpharma

Eltrombopag Polpharma is a medication used to stimulate the production of platelets in the blood. It is commonly prescribed for conditions affecting platelet levels, such as chronic immune thrombocytopenia. This oral medication is manufactured by Zaklady Farmaceutyczne Polpharma S.A. in the EU.

Eltrombopag is primarily used to increase platelet counts in individuals with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. It may also be used in other conditions where low platelet levels are a concern. The medication works by stimulating the bone marrow to produce more platelets, helping to reduce the risk of bleeding. Patients often wonder, 'What is Eltrombopag used for?' and the answer lies in its ability to support platelet production.

Common effects of Eltrombopag may include headaches, nausea, and dizziness. Some users might experience changes in liver function, so regular monitoring is advised. It is important to note that individual responses to the medication can vary, and not everyone will experience these effects. Always consult a healthcare provider for personalized advice.

Eltrombopag should be handled with care, especially for those with liver conditions or a history of liver problems. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. Regular blood tests may be recommended to monitor platelet levels and liver function. Always store the medication as directed and keep it out of reach of children.

Eltrombopag may interact with certain medications, including those that affect liver enzymes, such as CYP1A2 inhibitors or inducers. It is also advisable to avoid taking Eltrombopag with antacids containing magnesium or aluminum, as they can interfere with absorption. Always inform your healthcare provider about all medications you are taking to avoid potential interactions.